Highlights Aeolus Pharmaceuticals, Inc.

Equities

AOLS

US00765G1094

Market Closed - OTC Markets Other stock markets 08:14:28 11/04/2024 pm IST			5-day change	1st Jan Change
0.000001 ^USD	-99.00%		-.--%	-.--%

2017	Aeolus Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and First Nine Months Ended June 30, 2017	CI
2017	Aeolus Pharmaceuticals, Inc. Announces Fast Track Designation Granted to AEOL 10150 for Treatment of Patients With Lung Acute Radiation Syndrome Following a Radiologial or Nuclear Event	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Aeolus Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and First Nine Months Ended June 30, 2017	15/17/15	CI
Aeolus Pharmaceuticals, Inc. Announces Fast Track Designation Granted to AEOL 10150 for Treatment of Patients With Lung Acute Radiation Syndrome Following a Radiologial or Nuclear Event	08/17/08	CI
Aeolus Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended March 31, 2017	16/17/16	CI
Aeolus Pharmaceuticals, Inc. Initiates Phase 1 Study of AEOL 10150 in Healthy Normal Volunteers	23/17/23	CI
Aeolus Pharmaceuticals Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended September 30, 2016	21/16/21	CI
Aeolus Pharmaceuticals Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended June 30, 2016	16/16/16	CI
Aeolus Pharmaceuticals Inc. Announces Unaudited Consolidated Results for the Second Quarter and Six Months Ended March 31, 2016	16/16/16	CI
Aeolus Pharmaceuticals Inc. Announces Removal of FDA Clinical Hold on AEOL 10150	23/16/23	CI
Aeolus Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended December 31, 2015	17/16/17	CI
Aeolus Pharmaceuticals Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended September 30, 2015	22/15/22	CI
Aeolus Pharmaceuticals Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended June 30, 2015	17/15/17	CI
Barda Exercises $3 Million in Additional Contract Funding for Development of Aeol 10150 as Treatment for Acute Radiation Syndrome	26/15/26	CI
Aeolus Pharmaceuticals Inc. Reports Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended March 31, 2015	16/15/16	CI
Aeolus Pharmaceuticals, Inc. Announces Unaudited Consolidated Financial Results for the First Quarter Ended December 31, 2014	14/15/14	CI
Aeolus Pharmaceuticals Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended September 30, 2014	23/14/23	CI
Aeolus Pharmaceuticals Inc. Announces Presentation of Efficacy Data for AEOL 10150	20/14/20	CI
Aeolus Announces Results from Study of AEOL 10150 Doubles Survival Rate Against Lung Damage from Radiation Exposure	04/14/04	CI
Aeolus Pharmaceuticals, Inc. Files Investigational New Drug Application With US FDA to Enable Initiation of Human Safety Studies for the Development of AEOL as a Medical Countermeasure against Lung Damage from Radiation Exposure	20/14/20	CI
Aeolus Pharmaceuticals Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended June 30, 2014	15/14/15	CI
Aeolus Pharmaceuticals, Inc. Announces Data Demonstrating Efficacy of AEOL 10150 in Animal CEES Model of Mustard Gas Skin Exposure	18/14/18	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Aeolus Pharmaceuticals, Inc.

Equities

AOLS

US00765G1094

Highlights

Filters